reason report
elast demand drive consum growth pt
bottom line remain op believ lower
sequenc cost competit among custom continu
drive novaseq product upgrad cycl year
launch deliv anoth strong quarter driven except
strong consum pickup broadli across custom base
research clinic set believ increasingli
becom consum stori longer term novaseq provid path
genom make flowcel upgrad far frequent
instrument launch everi flowcel launch cost per gb
come drive increas sequenc volum expect
drive overal consum higher wake updat
reiter outperform rate move price target
deliv anoth except quarter ceo desouza novaseq
consum drove upsid quarter deliv top-lin y/
revenu growth ahead us
gross oper margin expand deliv
ep vs us street us becom
consum growth stori novaseq see signific
headroom drive sequenc cost leverag
dens pack nanowel improv chemistri like manifest
flowcel longer term novaseq consum grew
sequenti view surpass per instrument pull-
think go higher new flowcel come
novaseq elast demand continu deliv reduct
cost sequenc cost/gb drive market expans
introduct novaseq custom gain lower sequenc
cost near drive consum
growth seen quarter hiseq lab own novaseq
still see signific room grow recal custom
novaseq last year ad
new sequenc custom expand market even
consum genom demand drove growth quarter
post microarray revenu includ servic
quarter repres y/i growth growth driven
direct-to-consum dtc market global research applic
genotyp epigenet microarray strong across region
notabl china launch asian screen array provid ancestri
analysi major chines ethnic group
life scienc tool diagnost
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
guidanc rais may still conserv manag rais
revenu guidanc ep guidanc
cite higher consum revenu continu expect
high consum revenu novaseq
rais revenu estim ep
project reflect confid growth
edico genom like get incorpor novaseq box
believ acquir edico incorpor dragen
fpga field programm gate array within novaseq box
gener data shorter period time enabl faster turnaround
time sampl recal raw imag data convert
sequenc inform edico dragen platform could help speed
process
rate share outperform price target view
custom compet race reduc sequenc cost
manifest novaseq order believ sequenc market number
sampl depth coverag expand dramat next year novaseq
drive signific reduct sequenc cost hiseq
novaseq flow cell novaseq set path reach research
grade genom longer term price beyond high throughput platform
also continu drive double-digit growth desktop system includ nextseq
essenti key high growth market includ non-invas pre-nat test nipt
oncolog continu domin sequenc market world-wide address
market size accord life scienc genet test reproduct health
oncolog market share revenu market share sequenc unit
believ ilmn market share accuraci throughput enterpris level servic
product factor continu keep custom bound despit
custom consid higher price still direct strong competit sight
somewhat unbound market believ continu domin next-gen sequenc
keep drive sequenc cost lower lead elast demand sampl
share current trade price-to-earnings consensu ep averag
life scienc tool lst group multipl note potenti unbound
market opportun major popul develop develop world
touch sequenc form test next year use dcf
analysi beta long-term growth rate wacc arriv
price target revis estim believ remain strong forc
sequenc market see revenu growth continu outer year addit
believ long-term growth rate conserv estim given sequenc
repres somewhat unbound market opportun view still
applic continu explor beyond current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
dollar thousand except ep
servic revenu
revenu
estimate
compani report leerink partner estim note microarray total includ servic
flat slightli
modestli
y/i
modestli
expect increas
sequenti
expect slightli
lower vs
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report leerink partner estim
